Pegadricase
- Generic Name
- Pegadricase
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1040753-26-1
- Unique Ingredient Identifier
- 50XB37EKN8
- Background
Pegadricase is under investigation in clinical trial NCT01021241 (Safety and Efficacy Study of Intravenous Uricase-PEG 20).
- Associated Conditions
- -
- Associated Therapies
- -
SEL-212 Advances Refractory Gout Outcomes with Prolonged Treatment
SEL-212, a monthly two-component infusion therapy, improved patient-reported outcomes (PROs) in refractory gout patients after 3 doses, with further improvement after 6 doses, as shown in Phase 3 trials presented at ACR Convergence 2024.
Reducing Our Uncertainty Rating to Medium
Morningstar lowers Swedish Orphan Biovitrum's Uncertainty Rating to Medium from High due to diversified revenue via acquisitions in hematology and immunology. Hemophilia drug revenue concentration has declined from 60% in 2018 to 40% in 2023, expected to drop to mid-30s. New products like Altuviiio, SEL-212, and Vonjo will drive future growth. Fair value estimate remains SEK 343 with a narrow moat rating; shares appear undervalued.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath